Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the month of December 2022, specifically dated December 8, 2022. The report primarily serves to incorporate a press release regarding the presentation of additional clinical data for the company's product candidate IMC-C103C at the ESMO Immuno-Oncology 2022 Congress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or operational financial metrics.
Material Changes and Clinical Data
The primary material update concerns the Phase 1 expansion data for IMC-C103C, a bispecific T cell engager targeting MAGE-A4 in patients with ovarian cancer:
- Patient Cohort: Analysis included 33 heavily pre-treated patients with platinum relapsed/refractory ovarian cancer (70% had prior PARP inhibitor experience). This included 16 new patients and 17 previously reported patients with longer follow-up.
- Biomarker Expression: 39% (13/33) of patients were MAGE-A4 negative. Of the 55% (18/33) MAGE-A4 positive patients, the majority had low expression (median H score = 29 of 300), with only two patients having an H score greater than 150.
- Efficacy Results: Among 32 evaluable patients, one MAGE-A4 positive patient achieved a durable Partial Response (PR) lasting 12.7 months. Another patient with Stable Disease (SD) converted to an unconfirmed PR after the data cut-off. Five patients achieved SD.
- ctDNA Reductions: Reductions in circulating tumor DNA were observed in over half of the evaluable patients (12/22), including 7 with reductions of 50% or more, even in patients with low or zero MAGE-A4 expression.
- Safety Profile: The safety profile remained consistent with previous reports, characterized by T cell activation. No related adverse effects led to treatment discontinuation or death.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the scope and results of the IMC-C103C clinical trial, its safety profile, and therapeutic potential. Management highlighted several significant risks and uncertainties that could cause actual results to differ materially from expectations:
- Macroeconomic and Geopolitical Factors: Risks include worsening macroeconomic conditions, rising inflation, interest rates, capital market volatility, the ongoing COVID-19 pandemic, and the war in Ukraine.
- Operational and Supply Chain: Potential disruptions in clinical trial supply, commercial supply of KIMMTRAK, and global supply chain issues.
- Regulatory and Development: Risks related to obtaining regulatory approvals, delays in clinical trials due to enrollment or other factors, and the ability to demonstrate safety and efficacy.
- Commercialization: Challenges in establishing commercial infrastructure, launching products, and expanding approved indications for KIMMTRAK.
- Funding: The need to obtain additional funding on favorable terms, which may be impacted by market conditions.
Investor Verification Checklist
- Verify the durability of the Partial Response (12.7 months) in the single MAGE-A4 positive patient and the status of the patient converting from Stable Disease to Partial Response.
- Confirm the correlation between ctDNA reductions and clinical outcomes in patients with low or zero MAGE-A4 expression.
- Review the company's most recent Form 20-F for detailed financial position, cash runway, and liquidity status, as this 6-K does not contain financial data.
- Assess the impact of current macroeconomic conditions and geopolitical tensions on the company's ability to secure future funding and maintain supply chains.
- Monitor upcoming regulatory milestones for KIMMTRAK and the timeline for further clinical development of IMC-C103C.